

Rudolf Maria Huber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/977030/publications.pdf>

Version: 2024-02-01

171
papers

10,872
citations

81839

39
h-index

31818

101
g-index

194
all docs

194
docs citations

194
times ranked

13745
citing authors

#	ARTICLE	IF	CITATIONS
1	Screening for Lung Cancer in Individuals Who Never Smoked: An International Association for the Study of Lung Cancer Early Detection and Screening Committee Report. <i>Journal of Thoracic Oncology</i> , 2022, 17, 56-66.	0.5	49
2	Lung Cancer Screening in Persons Who Never Smoked Has to be Evaluatedâ€”A Response to Letter to the Editor. <i>Journal of Thoracic Oncology</i> , 2022, 17, e20-e21.	0.5	1
3	Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2021, 81, 87-100.	4.9	13
4	Effectiveness of a specialised breathlessness service for patients with advanced disease in Germany: a pragmatic fast-track randomised controlled trial (BreathEase). <i>European Respiratory Journal</i> , 2021, 58, 2002139.	3.1	12
5	New developments in locally advanced nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2021, 30, 200227.	3.0	9
6	Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9071-9071.	0.8	3
7	Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TILs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT). <i>Lung Cancer</i> , 2021, 160, 17-27.	0.9	10
8	BreathEase: rationale, design and recruitment of a randomised trial and embedded mixed-methods study of a multiprofessional breathlessness service in early palliative care. <i>ERJ Open Research</i> , 2021, 7, 00228-2020.	1.1	2
9	Lung Cancer Screening Considerations During Respiratory Infection Outbreaks, Epidemics or Pandemics: An IASLC Early Detection and Screening Committee Report. <i>Journal of Thoracic Oncology</i> , 2021, , .	0.5	11
10	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 404-415.	0.5	102
11	Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives. <i>Translational Lung Cancer Research</i> , 2020, 9, 1000-1014.	1.3	9
12	Targeted Natural Killer Cellâ€”Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial. <i>Clinical Cancer Research</i> , 2020, 26, 5368-5379.	3.2	42
13	Role of the erythropoietin receptor in Lung Cancer cells: erythropoietin exhibits angiogenic potential. <i>Journal of Cancer</i> , 2020, 11, 6090-6100.	1.2	7
14	Hedgehog Pathway Activation Might Mediate Pemetrexed Resistance in NSCLC Cells. <i>Anticancer Research</i> , 2020, 40, 1451-1458.	0.5	7
15	<p>Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin</p>. <i>Lung Cancer: Targets and Therapy</i> , 2020, Volume 11, 27-31.	1.3	7
16	Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations. <i>Oncology Research and Treatment</i> , 2020, 43, 289-298.	0.8	22
17	Identification of lung adenocarcinoma-specific exosome RNAs in peripheral blood by RNA-Seq analysis. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 1877-1886.	0.5	6
18	Abstract LB-076: Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy - results of a randomized phase II clinical trial (NSCLC-TK</p>/IL-2) (Eudra-CT Number 2008-002130-30). , 2020, , .		0

#	ARTICLE	IF	CITATIONS
19	Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans. <i>Chronic Respiratory Disease</i> , 2019, 16, 147997231877542.	1.0	11
20	Response assessment in non-small cell lung cancer immunotherapy: initial experiences in utilizing FDG PET/CT and the PD-1 blocker nivolumab. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 149-155.	0.3	1
21	Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. <i>Future Oncology</i> , 2019, 15, 1363-1383.	1.1	10
22	Continuous professional development: elevating thoracic oncology education in Europe. <i>Breathe</i> , 2019, 15, 279-285.	0.6	0
23	Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019, 28, 190024.	3.0	47
24	Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib. <i>Clinical Lung Cancer</i> , 2019, 20, 59-62.	1.1	9
25	Dermal Filler Injections Mimic Tumor Activity during Immune Checkpoint Inhibition. <i>Respiration</i> , 2018, 95, 362-363.	1.2	4
26	NSCLC Patients Harboring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy. <i>Respiration</i> , 2018, 95, 169-176.	1.2	14
27	The revised GOLD 2017 COPD categorization in relation to comorbidities. <i>Respiratory Medicine</i> , 2018, 134, 79-85.	1.3	45
28	Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 107-115.	1.0	22
29	Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 2693-2701.	0.8	124
30	Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries. <i>BMC Cancer</i> , 2018, 18, 1144.	1.1	9
31	Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. <i>RMD Open</i> , 2018, 4, e000714.	1.8	65
32	Less radiation, same quality: contrast-enhanced multi-detector computed tomography investigation of thoracic lymph nodes with one milli-sievert. <i>Radiologia Medica</i> , 2018, 123, 818-826.	4.7	5
33	Daily Chronic Intermittent Hypobaric Hypoxia Does Not Induce Chronic Increase in Pulmonary Arterial Pressure Assessed by Echocardiography. <i>Canadian Respiratory Journal</i> , 2018, 2018, 1-8.	0.8	0
34	Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach. <i>Respiratory Research</i> , 2018, 19, 110.	1.4	35
35	Heterogeneous pattern of differences in respiratory parameters between elderly with either good or poor FEV1. <i>BMC Pulmonary Medicine</i> , 2018, 18, 27.	0.8	4
36	Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study. <i>Annals of Oncology</i> , 2018, 29, 2076-2084.	0.6	74

#	ARTICLE	IF	CITATIONS
37	Pretherapeutic Inflammation Predicts Febrile Neutropenia and Reduced Progression-Free Survival after First-Line Chemotherapy in SCLC. <i>Oncology Research and Treatment</i> , 2018, 41, 506-512.	0.8	5
38	How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2103-2109.	3.3	11
39	Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9061-9061.	0.8	18
40	Response to checkpoint inhibition in lung cancer with molecular driver alterations.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21071-e21071.	0.8	1
41	Pleural and systemic cytokine expression profiles in patients with lung cancer. , 2018, , .		0
42	Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach. , 2018, , .		0
43	Retrospective analysis of treatment with Ivacaftor/Lumacaftor in patients with cystic fibrosis at the Munich Cystic Fibrosis Centers. , 2018, , .		0
44	Abstract B17: Interleukin-17 and -22 expression in non-small cell lung cancer. , 2018, , .		0
45	Assessment of lung function in a large cohort of patients with acromegaly. <i>European Journal of Endocrinology</i> , 2017, 177, 15-23.	1.9	8
46	Clinical relevance of the M1b and M1c descriptors from the proposed TNMÂ8 classification of lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 392-401.	1.0	5
47	Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 143-155.	1.1	26
48	Management of Progressive Pulmonary Nodules FoundÂduring and outside of CT Lung Cancer Screening Studies. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1755-1765.	0.5	9
49	Distinct computed tomography features of non-small-cell lung cancer in aÂEuropean population with EML4-ALK translocation. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 94-102.	0.3	1
50	Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort. <i>Respiratory Research</i> , 2017, 18, 14.	1.4	15
51	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 194-207.	0.5	186
52	ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?. <i>Lung Cancer</i> , 2017, 103, 1-5.	0.9	22
53	Pretherapeutic inflammation status and cytokine profile may predict response to immunotherapy in NSCLC patients. <i>Annals of Oncology</i> , 2017, 28, xi12.	0.6	1
54	Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine – a Phase I trial. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1081-1089.	1.0	18

#	ARTICLE	IF	CITATIONS
55	Frequency and clinical relevance of EGFR mutations and EML4–ALK translocations in octogenarians with non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5179-5186.	1.0	7
56	Cancer vaccination causes prolonged FDG accumulation in subcutaneous tissue. <i>Nuklearmedizin - NuclearMedicine</i> , 2017, 56, N22-N23.	0.3	1
57	Black and Blue. <i>Respiration</i> , 2017, 94, 465-466.	1.2	0
58	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinaseâ€“Positive Nonâ€“Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 2490-2498.	0.8	506
59	Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20502-e20502.	0.8	3
60	Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20503-e20503.	0.8	3
61	Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort. <i>PLoS ONE</i> , 2017, 12, e0177501.	1.1	37
62	Perception of climate change in patients with chronic lung disease. <i>PLoS ONE</i> , 2017, 12, e0186632.	1.1	4
63	Immune surveillance reactivation to improve overall survival in small cell lung cancer (SCLC): The randomized IMPULSE study. <i>Annals of Oncology</i> , 2016, 27, vi496.	0.6	0
64	A persistent pneumothorax? 5-year follow-up after diagnosis of Swyerâ€“Jamesâ€“MacLeod syndrome. <i>Breathe</i> , 2016, 12, e55-E58.	0.6	2
65	Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology. <i>Breathe</i> , 2016, 12, 249-255.	0.6	18
66	Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1954-1961.	0.5	10
67	Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. <i>Lung Cancer</i> , 2016, 100, 30-37.	0.9	3
68	SCLCâ€“State of the Art and What Does the Future Have in Store?. <i>Clinical Lung Cancer</i> , 2016, 17, 325-333.	1.1	48
69	Interleukin-22 is elevated in lavage from patients with lung cancer and other pulmonary diseases. <i>BMC Cancer</i> , 2016, 16, 409.	1.1	19
70	Thoracic lymph node delineation at dose-reduced (1ÂµSv) dose-modulated contrast enhanced MDCT: a retrospective pilot study. <i>Radiologia Medica</i> , 2016, 121, 644-651.	4.7	4
71	GILTâ€“A randomised phaseÂIII study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stageÂIII non-small cell lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 216-222.	1.0	66
72	Tracheobronchial stents in mucopolysaccharidosis. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2016, 83, 187-192.	0.4	8

#	ARTICLE	IF	CITATIONS
73	Symptoms and quality of life in relation to lung function and comorbidities in patients with idiopathic pulmonary fibrosis: INSIGHTS-IPF registry. , 2016, , .		2
74	Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).. Journal of Clinical Oncology, 2016, 34, 9007-9007.	0.8	25
75	Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status.. Journal of Clinical Oncology, 2016, 34, 9060-9060.	0.8	13
76	A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, TPS9110-TPS9110.	0.8	3
77	Interactions among Lung Cancer Cells, Fibroblasts, and Macrophages in 3D Co-Cultures and the Impact on MMP-1 and VEGF Expression. PLoS ONE, 2016, 11, e0156268.	1.1	32
78	Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies â€“ A Novel Stepwise Approach by Evaluation of Medication. PLoS ONE, 2016, 11, e0163408.	1.1	40
79	From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert Panel. Translational Lung Cancer Research, 2016, 5, 377-388.	1.3	5
80	Systematic analysis of self-reported comorbidities in the COSYCONET COPD cohort study by stepwise evaluation of medication. , 2016, , .		0
81	Pulmonary function during lung cancer therapy: A retrospective analysis of patients treated with monotherapy or multimodal treatments. , 2016, , .		0
82	The relevance of positron emission tomography response in non-small cell lung cancer. Memo - Magazine of European Medical Oncology, 2015, 8, 119-129.	0.3	1
83	Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?. Diagnostic Pathology, 2015, 10, 130.	0.9	70
84	Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe bronchiectasis and pulmonary embolism. International Journal of COPD, 2015, 10, 891.	0.9	16
85	Multispectral imaging and objective assessment of immune-tumor interactions in non-small cell lung cancer. , 2015, 3, .		1
86	Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) â€“ From Preclinical Studies to a Clinical Phase II Trial. Frontiers in Immunology, 2015, 6, 162.	2.2	87
87	Immunomodulatory switch maintenance therapy to improve overall survival in small cell lung cancer (SCLC): The randomized IMPULSE study. Annals of Oncology, 2015, 26, viii5.	0.6	0
88	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncology, The, 2015, 16, 257-265.	5.1	1,269
89	Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany. Pharmacoeconomics, 2015, 33, 1215-1228.	1.7	23
90	Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. European Respiratory Journal, 2015, 46, 186-196.	3.1	194

#	ARTICLE	IF	CITATIONS
91	Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)â€ Pretreated Nonâ€ Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease. <i>Journal of Thoracic Oncology</i> , 2015, 10, 156-163.	0.5	238
92	Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens. <i>Lung Cancer</i> , 2015, 90, 274-280.	0.9	30
93	Biological and phenomenological markers of ageing in patients with COPD and their relationship to CT emphysema scores. , 2015, , .		0
94	Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC. <i>Diagnostic Pathology</i> , 2014, 9, 165.	0.9	17
95	Neuroendocrine Tumors of the Bronchopulmonary System (Typical and Atypical Carcinoid Tumors): Current Strategies in Diagnosis and Treatment. Conclusions of an Expert Meeting February 2011 in Weimar, Germany. <i>Oncology Research and Treatment</i> , 2014, 37, 266-276.	0.8	44
96	Decreased expression of HLA-DQ and HLA-DR on cells of the monocytic lineage in cystic fibrosis. <i>Journal of Molecular Medicine</i> , 2014, 92, 1293-1304.	1.7	32
97	Preselection Based on Clinical Characteristics in German Nonâ€ Small-Cell Lung Cancer Patients Screened for EML4-ALK Translocation. <i>Journal of Thoracic Oncology</i> , 2014, 9, 109-113.	0.5	17
98	The European initiative for quality management in lung cancer care. <i>European Respiratory Journal</i> , 2014, 43, 1254-1277.	3.1	44
99	Response to Chemotherapy, Reexposure to Crizotinib and Treatment with a Novel ALK Inhibitor in a Patient with Acquired Crizotinib Resistance. <i>Respiration</i> , 2014, 88, 262-264.	1.2	10
100	Telomere length in circulating leukocytes is associated with lung function and disease. <i>European Respiratory Journal</i> , 2014, 43, 983-992.	3.1	103
101	Feasibility of microRNA Measurements in Routine Bronchoalveolar Lavage (BAL) and Bronchial Washings in Patients With Lung Cancer and Nonmalignant Pulmonary Diseases. <i>Chest</i> , 2014, 145, 342A.	0.4	1
102	Systemic treatment of elderly patients with NSCLC: Results of a German prospective observational study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19052-e19052.	0.8	0
103	Mature results of a randomized trial comparing two fractionation schedules of high dose rate endoluminal brachytherapy for the treatment of endobronchial tumors. <i>Radiation Oncology</i> , 2013, 8, 8.	1.2	20
104	Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naïve patients with metastasised small-cell lung cancer. <i>European Journal of Cancer</i> , 2013, 49, 2461-2468.	1.3	6
105	Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2013, 42, 1119-1133.	3.1	14
106	Cystic Fibrosis in Adults: Short-Term and Long-Term Reproducibility of the Brody Score for Lung Morphology inÂLow-Dose MDCT Scans. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2013, 186, 54-60.	0.7	3
107	Thoracic Oncology HERMES: a European syllabus towards a harmonised education and training of Thoracic Oncology specialists. <i>Breathe</i> , 2013, 9, 381-392.	0.6	5
108	Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe: Table 1â€. <i>European Respiratory Journal</i> , 2013, 42, 568-571.	3.1	23

#	ARTICLE	IF	CITATIONS
109	Spirometric Reference Values for Advanced Age from a South German Population. <i>Respiration</i> , 2013, 85, 210-219.	1.2	13
110	Interleukin-22 Is Frequently Expressed in Small- and Large-Cell Lung Cancer and Promotes Growth in Chemotherapy-Resistant Cancer Cells. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1032-1042.	0.5	62
111	Can MicroRNAs Improve the Management of Lung Cancer Patients? A Clinician's Perspective. <i>Theranostics</i> , 2013, 3, 953-963.	4.6	18
112	Reference Values of Impulse Oscillometric Lung Function Indices in Adults of Advanced Age. <i>PLoS ONE</i> , 2013, 8, e63366.	1.1	61
113	Smoking Cessation in Lung Cancer. <i>Deutsches A&#x0308;rzteblatt International</i> , 2013, 110, 719-24.	0.6	23
114	Chemotherapy and molecular biological therapy. , 2013, , 460-465.		0
115	Update on small cell lung cancer management. <i>Breathe</i> , 2012, 8, 314-330.	0.6	8
116	Toxic Epidermal Necrolysis after Pemetrexed and Cisplatin for Non-Small Cell Lung Cancer in a Patient with Sharp Syndrome. <i>Onkologie</i> , 2012, 35, 783-786.	1.1	11
117	Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells. <i>Aids</i> , 2012, 26, F31-F37.	1.0	137
118	Topotecan/Cisplatin Compared with Cisplatin/Etoposide as First-Line Treatment for Patients with Extensive Disease Small-Cell Lung Cancer: Final Results of a Randomized Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1432-1439.	0.5	41
119	Direct medical costs of COPD â€œ An excess cost approach based on two population-based studies. <i>Respiratory Medicine</i> , 2012, 106, 540-548.	1.3	53
120	Lung cancer diagnostic algorithm. <i>Lung Cancer</i> , 2012, 77, S4-S5.	0.9	1
121	Die StrahlensensitivitÃ¤t humaner Tumorzelllinien ist unabhÃ¤ngig von der basalen HIF-1Î±-Expression. <i>Strahlentherapie Und Onkologie</i> , 2012, 188, 353-358.	1.0	12
122	Effects of the Hedgehog pathway inhibitor GDC-0449 on lung cancer cell lines are mediated by side populations. <i>Clinical and Experimental Medicine</i> , 2012, 12, 25-30.	1.9	54
123	Influence of air pressure, humidity, solar radiation, temperature, and wind speed on ambulatory visits due to chronic obstructive pulmonary disease in Bavaria, Germany. <i>International Journal of Biometeorology</i> , 2012, 56, 137-143.	1.3	61
124	GILT study: Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): Final results of a phase (ph) III study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7001-7001.	0.8	22
125	Prophylactic cranial irradiation after reaching complete response, partial response, or stable disease in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (ProACT).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS7617-TPS7617.	0.8	1
126	The hedgehog pathway inhibitor GDC-0449 alters intracellular Ca ²⁺ homeostasis and inhibits cell growth in cisplatin-resistant lung cancer cells. <i>Anticancer Research</i> , 2012, 32, 89-94.	0.5	21

#	ARTICLE	IF	CITATIONS
127	Exhaled nitric oxide and influencing factors in a random population sample. <i>Respiratory Medicine</i> , 2011, 105, 713-718.	1.3	26
128	High blood pressure, antihypertensive medication and lung function in a general adult population. <i>Respiratory Research</i> , 2011, 12, 50.	1.4	20
129	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2011, 6, 244-285.	0.5	4,127
130	Organ-cocultures (COCs) for Long Term <i>in vitro</i> Studies of Lung Cancer Using 2-Photon Microscopy. <i>Technology in Cancer Research and Treatment</i> , 2011, 10, 275-279.	0.8	0
131	Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. <i>European Respiratory Journal</i> , 2011, 38, 239-243.	3.1	54
132	Concurrent Chemoradiation Therapy With Docetaxel/Cisplatin Followed by Docetaxel Consolidation Therapy in Inoperable Stage IIIA/B Non-Small-Cell Lung Cancer: Results of a Phase I Study. <i>Clinical Lung Cancer</i> , 2010, 11, 45-50.	1.1	5
133	Independent Information of Nonspecific Biomarkers in Exhaled Breath Condensate. <i>Respiration</i> , 2010, 80, 401-409.	1.2	20
134	The European Respiratory Society and European Society of Thoracic Surgeons clinical guidelines for evaluating fitness for radical treatment (surgery and chemoradiotherapy) in patients with lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2009, 36, 181-184.	0.6	114
135	Endoplasmic reticulum Ca ²⁺ -homeostasis is altered in small and non-small cell lung cancer cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 25.	3.5	55
136	Altered Ca ²⁺ -homeostasis of cisplatin-treated and low level resistant non-small-cell and small-cell lung cancer cells. <i>Cellular Oncology</i> , 2009, 31, 301-15.	1.9	17
137	Mechanisms Altering Airway Smooth Muscle Cell Ca ²⁺ Homeostasis in Two Asthma Models. <i>Respiration</i> , 2008, 76, 205-215.	1.2	19
138	Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide. <i>Chest</i> , 2008, 133, 1149-1154.	0.4	32
139	IL-13 Reverses the Effects of IL-13 and IL-4 on Bronchial Reactivity and Acetylcholine-Induced Ca ²⁺ Signaling. <i>International Archives of Allergy and Immunology</i> , 2007, 142, 199-210.	0.9	30
140	Is Lung Cancer in Never-smokers a Different Disease? "Back to the Figures. <i>Journal of Thoracic Oncology</i> , 2007, 2, 787-788.	0.5	5
141	Pulmonary Function in Patients With Type 1 Diabetes Before and After Simultaneous Pancreas and Kidney Transplantation. <i>Transplantation</i> , 2007, 83, 566-569.	0.5	19
142	In-vivo kinetics of inhaled 5-Aminolevulinic acid-Induced Protoporphyrin IX fluorescence in bronchial tissue. <i>Respiratory Research</i> , 2007, 8, 33.	1.4	16
143	A6-03: A possible role for the intracellular Ca ²⁺ -homeostasis in the development of cisplatin-resistance in squamous lung carcinoma cells. <i>Journal of Thoracic Oncology</i> , 2007, 2, S327.	0.5	0
144	Topotecan Therapy in Patients with Relapsed Small-Cell Lung Cancer and Poor Performance Status. <i>Clinical Lung Cancer</i> , 2006, 8, 130-134.	1.1	7

#	ARTICLE	IF	CITATIONS
145	Ca ²⁺ -signaling in airway smooth muscle cells is altered in T-bet knock-out mice. <i>Respiratory Research</i> , 2006, 7, 33.	1.4	21
146	Acute effects of hemodialysis on lung function in patients with end-stage renal disease. <i>Wiener Klinische Wochenschrift</i> , 2006, 118, 108-113.	1.0	16
147	Oral Vinorelbine and Cisplatin with Concomitant Radiotherapy in Stage III Non-Small Cell Lung Cancer (NSCLC): A Feasibility Study. <i>Oncology Research and Treatment</i> , 2006, 29, 137-142.	0.8	12
148	Rotation Frequency of Human Bronchial and Nasal Epithelial Spheroids as an Indicator of Mucociliary Function. <i>Respiration</i> , 2006, 73, 664-672.	1.2	9
149	Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non-Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 4397-4404.	0.8	122
150	Improvement of Alveolar Glutathione and Lung Function but Not Oxidative State in Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 822-828.	2.5	104
151	MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2004, 31, 86-91.	1.4	134
152	Cystic Fibrosis Diagnosed in a 38-Year-Old Man with Long-Standing HIV Infection. <i>Clinical Infectious Diseases</i> , 2004, 39, 438-439.	2.9	2
153	Treatment of Benign and Malignant Tracheobronchial Obstruction with Metal Wire Stents: Experience with a Balloon-Expandable and a Self-Expandable Stent Type. <i>CardioVascular and Interventional Radiology</i> , 2004, 27, 339-43.	0.9	11
154	Molecular oncology – perspectives in lung cancer. <i>Lung Cancer</i> , 2004, 45, S209-S213.	0.9	27
155	The use of mini-organ cultures of human upper aerodigestive tract epithelia in ecogenotoxicology. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2004, 561, 63-73.	0.9	39
156	Detection of Melanoma Antigen-A Expression in Sputum and Bronchial Lavage Fluid of Patients With Lung Cancer. <i>Chest</i> , 2004, 125, 164S-166S.	0.4	28
157	Kinetics of 5-Aminolevulinic Acid-Induced Fluorescence in Organ Cultures of Bronchial Epithelium and Tumor. <i>Respiration</i> , 2002, 69, 445-450.	1.2	12
158	Combined transcriptome and genome analysis of single micrometastatic cells. <i>Nature Biotechnology</i> , 2002, 20, 387-392.	9.4	269
159	Sequential chemo- and radiochemotherapy with weekly paclitaxel (Taxol®) and 3D-conformal radiotherapy of stage III inoperable non-small cell lung cancer. <i>Lung Cancer</i> , 2001, 32, 163-171.	0.9	17
160	Fiberoptic Bronchoscopic Balloon Dilatation in Malignant Tracheobronchial Disease. <i>Chest</i> , 2001, 120, 43-49.	0.4	129
161	Genotoxicity of Nitroso Compounds and Sodium Dichromate in a Model Combining Organ Cultures of Human Nasal Epithelia and the Comet Assay. <i>Orl</i> , 2001, 63, 141-147.	0.6	24
162	Laser resistance of expandable metal stents in interventional bronchoscopy: An experimental evaluation. <i>Lasers in Surgery and Medicine</i> , 2001, 29, 70-72.	1.1	7

#	ARTICLE	IF	CITATIONS
163	High Frequency Jet Ventilation in Interventional Fiberoptic Bronchoscopy. Anesthesia and Analgesia, 2000, 90, 1436-1440.	1.1	53
164	High-dose-rate brachytherapy: dose escalation in three-dimensional miniorgans of the human bronchial wall. International Journal of Radiation Oncology Biology Physics, 2000, 46, 1267-1273.	0.4	8
165	Flexible bronchoscopy: a safe method for metal stent implantation in bronchial disease. Annals of Thoracic Surgery, 2000, 69, 398-401.	0.7	47
166	Three-Dimensional In Vitro Cocultivation of Lung Carcinoma Cells with Human Bronchial Organ Culture as a Model for Bronchial Carcinoma. American Journal of Respiratory Cell and Molecular Biology, 1999, 21, 200-208.	1.4	28
167	Elastic deformation properties of implanted endobronchial wire stents in benign and malignant bronchial disease: A radiographic in vivo evaluation. CardioVascular and Interventional Radiology, 1999, 22, 103-108.	0.9	8
168	Adrenomedullin: A Player at High Altitude?. Chest, 1998, 113, 1428.	0.4	15
169	Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors. International Journal of Radiation Oncology Biology Physics, 1997, 38, 533-540.	0.4	123
170	Palliative Endobronchial Brachytherapy for Central Lung Tumors. Chest, 1995, 107, 463-470.	0.4	81
171	Growth-hormone releasing hormone in a bronchial carcinoid. Cancer, 1991, 67, 2538-2542.	2.0	17